CIRCULOGENE testing rapidly matches young patient with targeted therapy for rare non-small-cell lung cancer genetic variation.

An oncologist referred a blood sample on his 44-year-old female non-small cell lung cancer (NSCLC) patient to CIRCULOGENE for its personalized cancer testing expertise.  In just six days, CIRCULOGENE matched the patient’s specific cancer to a potential therapy and identified multiple clinical trial opportunities.

Using a single tube of blood, the physician ordered a personalized #gene profile from CIRCULOGENE to test for circulating genetic mutations and tumor biomarkers, including:

  • DNA Mutations
  • RNA Fusions
  • PD-L1 Expression
  • MSI (microsatellite instability)

Results:

CIRCULOGENE detected a RARE ROS1 fusion and MSI-H positivity. The targeted therapy for the ROS1 Fusion genetic variation is Xalkori® (crizotinib), used in the treatment of NSCLC that has spread to other parts of the body. Treatment with Xalkori was initiated immediately.

Clinical Benefit:

“ROS1 is very rare, but for this young patient and her oncologist, CIRCULOGENE liquid biopsy testing quickly returned a personalized lung cancer profile with actionable results. This enabled the immediate initiation of targeted therapy and identification of a second-line therapy, Keytruda, matched to the patient based on the MSI-H defect.” – Chen Yeh, Chief Scientific Officer